tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tiziana Life Sciences CEO Buys Shares, Signaling Confidence in Innovative Therapies

Story Highlights
Tiziana Life Sciences CEO Buys Shares, Signaling Confidence in Innovative Therapies

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tiziana Life Sciences ( (TLSA) ) has shared an announcement.

On September 9, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, purchased 193,848 shares of the company’s common stock at $1.65 per share. This move underscores confidence in the company’s strategic direction, particularly in advancing its lead candidate, intranasal foralumab, which is undergoing trials for treating non-active secondary progressive multiple sclerosis. This development could potentially enhance Tiziana’s market position and stakeholder confidence in its innovative therapeutic approaches.

The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical development for treating neuroinflammatory and neurodegenerative diseases.

Average Trading Volume: 345,441

Technical Sentiment Signal: Buy

Current Market Cap: $185M

For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1